Kim Barbara Luley

Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial

Salah‐Eddin Al‐Batran, Nils Homann, Claudia Pauligk et al. · The Lancet · 2019 · 2.6K citations · Full text

Medicine, Oncology, Perioperative Medicine +17

Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial

Salah‐Eddin Al‐Batran, Ralf‐Dieter Hofheinz, Claudia Pauligk et al. · The Lancet Oncology · 2016 · 739 citations

Medicine, Oncology, Pharmacology +16

Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer

Salah‐Eddin Al‐Batran, Nils Homann, Claudia Pauligk et al. · JAMA Oncology · 2017 · 474 citations · Full text

Medicine, Oncology, Surgery +15

Perioperative chemotherapy with docetaxel, oxaliplatin, and fluorouracil/leucovorin (FLOT) versus epirubicin, cisplatin, and fluorouracil or capecitabine (ECF/ECX) for resectable gastric or gastroesophageal junction (GEJ) adenocarcinoma (FLOT4-AIO): A multicenter, randomized phase 3 trial.

Salah‐Eddin Al‐Batran, Nils Homann, Harald Schmalenberg et al. · Journal of Clinical Oncology · 2017 · 239 citations

Medicine, Oncology, Perioperative Medicine +15

Impact of pathologic complete response on disease-free survival in patients with esophagogastric adenocarcinoma receiving preoperative docetaxel-based chemotherapy

Sylvie Lorenzen, Peter Thuss‐Patience, Salah‐Eddin Al‐Batran et al. · Annals of Oncology · 2013 · 118 citations

Medicine, Oncology, Chemotherapy +10